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INTRODUCTION
Psoriasis is a common, chronic, inflammatory papulosquamous
disorder of skin in which both genetic and environmental factors have a
critical role. It is characterized  by dull red, scaly, indurated plaque,
having a chronic course with remission and exacerbation.
It is a widespread disease with worldwide prevalence of 0.6-
4.8%(1). Among the patients attending hospitals in India, the prevalence is
about 0.8-5.6%(2). It affects all the age groups, and its prevalence  in
children younger than 18 years is 0.71%(3).
Comorbidity is the occurrence of one or multiple disorder(s) in
association with a given disease(4,5). This has gained interest in various
fields of medicine in recent times and often appears to be due to common
pathogenic pathways(4,6). Comorbidities tend to arise in complex
disorders, they are frequently multigenic & multifactorial and most often
demonstrate an inflammatory background(4). Psoriasis is associated with
numerous comorbidities which  has a major impact on severely affected
patients(4,7).
Knowledge of comorbidities in psoriasis is of substantial
importance because of the following aspects:
1. The concomitance of other diseases leads to intake of medications
that could affect the onset, severity and course of psoriasis
2. Medications used to treat psoriasis may positively or negatively
influence the comorbidities
3. An association to distinct diseases could help to obtain a deeper
insight into the pathogenesis of psoriasis
4. Therapeutic management of patients with psoriasis needs to be
adapted to the prevalence of other diseases and medication(8).
As dermatologists are often the first consulted healthcare
specialists by patients with psoriasis, we should be aware of these
comorbidities and this study is designed for the purpose of studying these
comorbidities.
REVIEW OF LITERATURE
Epidemiological studies have demonstrated  a significant
association between psoriasis and other diseases, known as
comorbidities(8,9). Nearly half of the psoriatic patients aged over 65 years
have atleast three comorbidities and two third have two or more
comorbidities(6). They often become clinically manifest years after the
onset of disease(10) in  moderate to severe psoriasis(11).
Emerging comorbidities in psoriasis  include cardiovascular
disease and metabolic syndrome(12). The components of metabolic
syndrome are diabetes mellitus, hypertension, obesity(13) and
dyslipidemia(12). Of these diabetes mellitus shows the highest frequency
followed by hypertension(14).
The systemic disorders associated with psoriasis include non-
alcoholic fatty liver disease(15), gout, ulcerative colitis, crohn’s disease(14) ,
depression(16) and  osteoporosis(17).
Other comorbid conditions significantly associated with psoriasis
are sleep disorders or insomnia, chronic obstructive pulmonary disease
and gastroesophageal reflux disease(18). Renal failure and hepatitis are the
least likely comorbidities(19). Psoriatic patients are at the increased risk of
malignancy particularly non-melanoma skin cancer and
lymphoproliferative diseases(20).
Like in adults, psoriasis is associated with significant comorbidity
in children too. A German study shows that the overall rate of
comorbidities in psoriasis in those aged under 20 years were high when
compared to controls. Increased rates of hyperlipidemia, obesity,
hypertension, diabetes mellitus, rheumatoid arthritis and crohn’s disease
were observed in them(3).
Epidemiological studies from US, UK, Italy, other European
countries, Taiwan and Israel confirm the association between psoriasis
and metabolic syndrome, but only scanty data are available on this
subjects from South Asian countries(11).
In a study carried out in Chennai, Tamilnadu, with 120 psoriasis
patients, 55.8%  had comorbidities and the results is shown in the chart
given below(21).
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Table showing percentage distribution of comorbid conditions in
psoriasis(21).
Co – morbid conditions Number ofpatients
Percentage of
patients
DM 14 11.6%
HT 17 14.1%
Both DM and HT 15 12.5%
Others
Obesity 8 6.6%
Thyroid disorder 4 3.3%
Ischaemic Heart
Disease 4 3.3%
Hyper
Cholesterolemia 5 4.1%
Total 67 55.8%
PATHOGENESIS
The connection between psoriasis and atherosclerosis may be due
to an increased prevalence of atherosclerotic risk factors as well as to the
chronic inflammation that occurs in psoriasis.
In order to understand the relationship between coronary artery
disease and psoriasis, it is important to review the commanalities in their
pathophysiology.
Psoriasis is an immune disease, characterized by inappropriate
activation of cellular immune system directed against self-antigens(22).
For more than a decade, the fundamental pathophysiology has been
thought to be related to T helper 1(Th1) mediated cellular dysfunction
which produces systemic inflammation and a concurrent increase in
cytokine production(22,23).
In short, an antigen-presenting cell (APC) identifies and processes
a yet-to-be identified antigen in the skin. APC then presents the processed
antigen in a major histocompatability  class II-restricted fashion, and
activates naive T cells in the local lymphnodes, resulting in a clonal
expression of  Th1 arm under the influence of interleukin (IL)-2. These
activated  Th1 clones enter the circulation and through the process of
diapedesis, they permeate the endothelium and cause an inflammatory
reaction in the affected skin. The  cytokines driving this response are, of
course are tumor necrosis factor(TNF-?), IL-2  and interferon(IFN)-? of
Th1 profile. This  in turn, leads to the recruitment of other immune cells
and expression of vascular endothelial growth factor, leading to vascular
proliferation. Krueger and Bowcock characterized the process as many
interactive responses between infiltrating leukocytes, resident skin cells,
and an array of pro-inflammatory cytokines, chemokines and chemical
mediators produced in the skin under regulation of cellular immune
system. Heredity and environmental factors may interact with this
complex inflammatory process to modify further the clinical expression
of  the disease. The severity of the disease is related to this inflammatory
response.
Similar inflammatory processes occur in the development of
atherosclerosis, a chronic immunoinflammatory disease of arterial wall.
Inflammation is crucial in all stages of atherosclerosis. It is implicated not
only in the formation of fatty streaks, but also with adverse clinical
vascular events. During the rupture of an unstable atherosclerotic plaque,
activated inflammatory cells within the plaque secrete matrix proteases
leading to the degradation of extracellular matrix proteins, weakening of
the fibrous cap, leading to rupture and thrombus formation. The
activation of inflammatory process and upregulation of  Th1 mediated
cytokine cascades (with IFN-?, TNF-?, IL-1and IL-6) is a possible trigger
for acute coronary syndromes as well as psoriasis, as described above (22).
Decades of chronic angiogenesis necessary to maintain the
psoriasis phenotype could also theoretically be related to cardiovascular
disorders through exhausting the pool of endothelial precursor cells
(EPCs) in the bone marrow, which are believed to play a critical role in
maintenance of endothelial integrity, function, and repair. Furthermore,
many of the inflammatory mediators and cell adhesion molecules
increased in psoriasis can directly promote endothelial cell activation and
dysfunction, leading to cardiovascular disease. Consistent with this
hypothesis, patients with psoriatic arthritis without cardiovascular risk
factors or clinically evident cardiovascular disease have been shown to
exhibit endothelial dysfunction.   Chronic psoriasis also impacts oxidative
metabolic pathways which may have systemic implications, especially
with respect to atherosclerosis and Myocardial infarction. Inflamed
psoriatic skin generates free radicals, reactive oxygen species (ROS) and
results in superoxide anion liberation. On the cellular level, even those
with mild psoriasis display an disequilibrium between markers of
oxidative stress and antioxidants. Psoriasis may further promote oxidative
stress through an association with decreased folic acid levels and
increased homocysteine levels(13).
In addition, local stimulation of smooth muscle cells in the arterial
wall amplifies the inflammatory response and promotes a precoagulant
milieu. As macrophages, T lymphocytes and smooth muscle cells are
activated there is a further progressive amplification of proinflammatory
cytokines, chemokines and growth factors that also promote
atherogenesis(22).
Although inflammatory cytokines such as TNF? have been
extensively studied, emerging data have recently demonstrated the central
role of IL-20 and IL-17 in the pathogenesis of psoriasis. IL-17 is secreted
by a new subclass of CD4+ cells, the Th17 cells  and  this   plays  an
important role in the pathogenesis of psoriasis. It also  activates
inflammation in a variety of organ systems. For example, IL-17 is
elevated in the sera of patients with unstable coronary artery disease and
is also preferentially expressed in animal models of aged coronary
arteries that are susceptible to ischemia(13).
Interestingly recent data suggest that a unique T-cell subset, T-IL-
17, mediates IL-12 and IL-23 and these have an important role in the
pathogenesis of psoriatic lesions. Monoclonal antibodies against a subunit
shared by IL-12  and IL-23 are undergoing therapeutic trials as promising
new therapies for psoriasis. It is the circulating IL-12 that is thought to be
the link between inflammation and Th1 type cytokine production in
coronary atherosclerosis(22).
It is important to note that the risk of coronary artery disease is also
increased in other systemic inflammatory diseases such as rheumatoid
arthritis and systemic lupus erythematosus, and hence systemic
inflammation in psoriasis is in part responsible for the increased risk of
myocardial infarction(24).Several groups have proposed similar hypothesis
and have implicated both proinflammatory cascades as well as
angiogenesis(22).
The relationship between psoriasis and metabolic syndrome is
likely to be due to the chronic inflammatory nature of psoriasis with
increased TNF?(10,12). Similar to psoriasis, the metabolic syndrome is
characterized by an increase in the activity of type 1 helper T cells(25).
Recent studies investigating the effect of Tumor Necrosis Factor
antagonists on the treatment of cardiovascular disease and metabolic
syndrome support this concept(12).
It is hypothesized that proinflammatory cytokines constribute to
obesity, dyslipidemia, atherogenesis, peripheral insulin resistance, type II
diabetes, hypertension etc. This is supported by following observations.
1. The adipocytes release adipocytokines or adipokines e.g.
adiponectin, leptin, resistin, plasminogen activator inhibitor type 1
as well as TNF-?. Resistin mediates insulin resistance.
2. TNF-? and IL-6 induce insulin resistance, dyslipidemia and
procoagulant effect. IL-6 causes increased C reactive protein levels
and erythrocyte sedimentation rate. Elevated erythrocyte
sedimentation rate in psoriasis and obesity may be the predictor of
coronary heart disease(11).
3. The thiazolidinediones are beneficial in both diabetes and psoriasis.
The thiazolidinediones   have anti-inflammatory properties. This
supports  the role of  inflammation between them(26).
4. Systemic inflammation in psoriasis leads to endothelial dysfunction
i.e.imbalance of vasoconstrictor(endothelin-1) and vasodilator
factors (nitric oxide). TNF-? release in psoriasis induces insulin
resistance which inturn reduces the activity of endothelial NO
synthetase; however, mitogen activated kinase e.g. p38MAPK
remains active and adhesion molecules and vasoconstrictors are
synthesized. Increased endothelin levels constribute to the
pathogenesis of systemic and pulmonary hypertension.
5. In psoriasis, increased levels of angiotensin converting enzyme,
endothelin-1 and renin are seen. Angiotensin II is a vasoconstrictor,
degrades bradykinin (a vasodilator) and enhance the levels of
plasminogen activator inhibitor-1, thus promoting thrombotic
state(11).
6. Immunocytes and keratinocytes in the psoriatic skin produce
angiogenic factors, such as VEGF, which promote angiogenesis
and endothelial cell activation. VEGF levels are increased in
plaques of psoriasis and serum concentration of VEGF correlates
with clinical severity of disease. VEGF is also increased in
hyperinsulinemic states like metabolic syndrome in which
adipocytes are its primary source. Therefore, it is possible that
hyperinsulinemic states such as obesity and metabolic syndrome
may promote susceptibility to psoriasis or exacerbate existing
psoriasis not only through their role in promoting inflammation,
but also through increased and sustained levels of circulating
VEGF(13).
7. Most of the psoriasis patients with moderate to severe disease get
depression which develops into a vicious cycle with increased
alcohol consumption, increased food intake and reduced physical
activity, all aggravating the associated obesity and metabolic
syndrome.
8. PSORS8 locus in psoriasis overlaps with Crohn's disease locus on
long arm of chromosome 16(11). There is a postulated role of
bacteria in both of them and the response to therapy targeted at
TNF-?(27).
9. Data from both animal and human studies suggest that the
cytokines TNF?, IFN-? and other Type I cytokines are linked to
depression(28).
10. A study from Netherland states that the biological explanation for
Osteoporosis in Psoriasis is increased levels of TNF-?(17).
Finally, genetics also  play a critical role in susceptibility to
psoriasis and metabolic disorders. Over 20 genetic loci containing
varying numbers of genes, many of which have no known function, have
been associated with psoriasis susceptibility. Of these, several are
associated with susceptibility to metabolic diseases. The psoriasis
susceptibility loci PSORS2, PSORS3, and PSORS4 are also associated
with loci of susceptibility for metabolic syndrome, type 2 diabetes,
familial hyperlipidemia and cardiovascular disease. Furthermore,
individual genes associated with psoriasis such as CDKAL1, are  also
associated with type 2-diabetes. Genes with known function in
cardiovascular risk, such as the ApoE4 isoform of ApoE are significantly
more prevalent in chronic plaque and guttate psoriasis than in controls(13).
CARDIOVASCULAR DISEASES
In present days, attention is given to the association between
psoriasis, cardiovascular risk factors and myocardial
infarction(24,29,30,31,32,33). The cardiovascular risk factors of  hypertension,
diabetes mellitus, obesity, smoking and dyslipidemia  have been found to
be more prevalent in patients with psoriasis(24,30,34,35). Obesity and diabetes
have been shown to be more prevalent in severe disease than in patients
with mild disease.
After controlling these cardiovascular risk factors, psoriasis confers
an independent risk for myocardial infarction(24,36,37,38). The increased risk
seems to be  higher in younger patients(35,39,40,41) and  in severe
disease(35,39,40,41,42) and it is due to the inflammatory nature of psoriasis
causing inflammatory change in coronary arteries(43).This leads to
increased mortality compared with those without psoriasis(24,44).
The age adjusted proportion of atherosclerosis is significantly
higher in psoriatic patients(45) and there is an association between
atherosclerosis and the use of phototherapy. Traditional systemic
antipsoriatic agents negatively affect cardiometabolic comorbidities and
have an important interactions with drugs commonly used in psoriasis
patients(46).
Methotrexate therapy for psoriasis has significantly reduced the
risk for vascular disease. Concomitant use of folic acid with methotrexate
reduces the risk further. Low to moderate cumulative dose of
methotrexate appears to be more beneficial than the higher dose(47).Hence
patients with psoriasis should be treated effectively and encouraged to
correct their modifiable cardiovascular risk factors(46).
Hyperuricemia that occurs in psoriasis is also an independent risk
factor for cardiovascular disease and ischaemic storke(48).
CEREBROVASCULAR AND PERIPHERAL VASCULAR
DISEASES
Since atherosclerosis is a systemic disease, it is reasonable to
assume that if myocardial infarction is increased in patients with
psoriasis, other manifestations of atherosclerosis, such as cerebrovascular
disease and peripheral arterial disease might also be increased(24,49). Stroke
is a leading cause of mortality, and many of those who are fortunate
enough to survive are left with a functional disability. Peripheral arterial
disease, which can cause symptomatic claudication and may lead to
amputation, is also associated with an increased risk of cerebrovascular
disease, myocardial infarction and death(24).
A cross-sectional study was done with 32 severe psoriasis patients
(defined as >10 year history of plaque-type psoriasis verified by a
dermatologist and with >2 episodes of systemic or inpatient treatment)
and 32 matched outpatient controls, to see the prevalence of coronary
artery disease using spiral computed tomography to measure coronary
artery calcification. Severe psoriasis patients had a higher prevalence of
coronary artery disease (CAD) compared with controls (59% vs. 28%
respectively, P = 0.02), and had more severe CAD based on the coronary
artery calcification scores(13).
A population-based cohort study of greater than 1,30,000 patients
with psoriasis in the UK demonstrated an increased relative risk of
myocardial infarction (MI), even after controlling the major
cardiovascular risk factors. In particular, younger patients with severe
psoriasis (defined as having received systemic psoriasis treatment) had
the highest relative risks for MI. For example, a 30-year-old patient with
severe psoriasis had a 3.1 (95% CI: 2.0-4.9) relative risk of  MI, whereas
a 60-year-old patient with severe psoriasis had a 1.36 (95% CI:1.1-1.6)
relative risk(13).
In a study conducted at U.K., among  44,164  psoriasis cohort, 596
(1·4%) patients were having myocardial infarction and among the
2,19,784  comparison cohort, 2459 (1·1%) had myocardial infarction.
This states that psoriasis patients are 1.21 times increased risk of getting
myocardial infarction when compared to controls(50).
Multivariate analysis was done by Srjdan Prodanovich et.al, with
3236 psoriasis patients and  2500 patients  without psoriasis (controls) to
determine the association of psoriasis with vascular diseases. After age,
sex and history of hypertension, diabetes, dyslipidemia  and smoking
status were matched, patients with psoriasis had significantly high rate of
atherosclerosis than the controls (OR: 2.18; 95% CI: 1.59-3.01). Patients
with psoriasis were also more likely to have  a diagnosis of ischemic heart
disease (OR: 1.78;  95% CI: 1.51-2.11), cerebral vascular disease
(OR: 1.70; 95% CI: 1.33-2.17), or peripheral arterial disease (OR: 1.98;
95% CI: 1.38-2.82)(24).
METABOLIC SYNDROME
Metabolic Syndrome is also known as syndrome X or insulin
resistance syndrome. It describes a constellation of metabolic
derangements that includes insulin resistance, hypertension, dyslipidemia
(low HDL and elevated Triglycerides), central or visceral obesity, type 2
diabetes, impaired fasting glucose / impaired glucose tolerance and
accelerated cardiovascular disease(51,52,53,54).
A study conducted by Christophers, E. et.al., with 600 psoriatic
patients, supports  the  concept  that  psoriasis  patients  are  at  risk of
obesity, hypertension and  diabetes as well as dyslipidemia and chronic
heart disease. Taken together there is accumulating evidence that, similar
to Rheumatoid arthritis  patients, psoriatic patients tend to develop signs
of systemic disease known as metabolic syndrome(4).
As per the National Cholesterol Education Programme's Adult
Panel III (ATP III), Metabolic syndrome is clinically identified by its risk
factors. Any three of the following risk factors to be present for the
clinical diagnosis of metabolic syndrome(25,30).
No. Risk Factor Defining level
1. Abdominal obesity
Men (Waist circumference)
Women (Waist circumference)
> 102 cm (>40 inches)
> 88 cm (>35 inches)
Or specific medication
2. Triglycerides > 1.7 mmol/L (>150 mg/dl)
Or specific medication
3. HDL
Men
Women
< 1.0 mmol/L (<40 mg/dl)
< 1.3 mmol/L (<50 mg/dl)
Or specific medication
4.
Blood Pressure
? 130/85mmHg
Or specific medication
5. Fasting Glucose >100mg/dl
The presence of abdominal obesity is more highly correlated with
metabolic risk factors than the elevated body mass index (BMI).
Therefore a simple measure of waist circumference is recommended to
identify the BMI component of the metabolic syndrome (55).
For measuring the waist circumference, the upper hip bone is
located at first and the measuring tape is placed at the level of the upper
most part of the hip bone around the abdomen (ensuing the tape measure
was horizontal). The tape measure was snug but did not cause
compression on the skin. Venous samples can be taken after the subjects
have been fasted overnight (at least 8 hours) to estimate the  Serum
cholesterol, triglycerides, HDL, LDL and Plasma glucose. Blood pressure
can be recorded as the average of two measurements after subjects have
been seated for about five minutes(25).
A study conducted by Safiye Kutlu et.al., by including 250
psoriatic patients (131 females, 119 males; age range: 18?85; mean age:
41.39 ± 14.7) states that metabolic syndrome was found in 30.8% of
patients with psoriasis, and  Type 2 psoriasis was more common in
them(56).
Another study with 338  psoriasis cases and 334 controls, states a
higher prevalence of metabolic syndrome in cases than in controls [30·1%
vs. 20·6%, odds ratio (OR- 1·65, 95% CI -1·16 to 2·35; P = 0·005] after
controlling for sex and age. The high prevalence of metabolic syndrome
in psoriatic patients was confirmed in all age classes of 40 years and
older. Metabolic syndrome was present in 35·2% of patients with
psoriatic arthritis(P = 0·003). Prevalence of metabolic syndrome was not
correlated to severity of psoriasis, in particular, there was no difference in
the prevalence of metabolic syndrome in patients with a PASI score
lower or higher than 10 (30·1% vs. 29·4%, respectively; P = 0·9), or in
patients with BSA involvement lower or greater than 10% (32·2% vs.
28·4%, respectively; P = 0·4). There were no differences in the
prevalence of metabolic syndrome between men and women, but it was
more frequent after the age of 40 in both cases and controls. Waist
circumference > 102 cm in men or > 88 cm in women, and
triglyceridaemia > 1·7 mmol L?1 were significantly more prevalent in
cases than in controls. In contrast, there were no significant differences
regarding the prevalence of low HDL cholesterol, hypertension and
fasting plasma glucose between cases and controls. This study  found  a
mild but significant correlation between severity of psoriasis and
triglyceridaemia in patients with psoriasis (P = 0·04) and between plasma
fasting glucose and triglyceridaemia in subjects with metabolic syndrome
(P = 0·0006).  This study found no significant correlation between
psoriasis severity with waist circumference, blood pressure, fasting
plasma glucose and body weight(57). The higher prevalence of metabolic
syndrome in patients with psoriasis(57,58), could play a relevant role in
accelerating atherosclerosis(57).
But the relationship between metabolic syndrome and the severity
of psoriasis is controversial. Sommer et al., reported an increased
prevalence of metabolic syndrome in patients with moderate-to-severe
psoriasis. In contrast, Gisondi et al., and Takahashi et al., detected no
correlation between the severity of psoriasis and metabolic syndrome.
Again, it was demonstrated that the duration and severity of psoriasis has
no effect on insulin resistance (56).
A study by Nuzhatun Nisa et.al included 150 chronic plaque
psoriasis cases and 150 controls. A higher prevalence of metabolic
syndrome in cases (42/150= 28%) than in controls (09/150 = 6%) with an
odds ratio (OR) of 6.09, P < 0.05 was found after adjusting for
confounding by age. This study also observed the higher prevalence of
individual components of metabolic syndrome like triglyceride levels
>150 mg/dl (73/150 vs 24/150 OR= 4.98, P=0.0005), fasting plasma
glucose > 100 mg/dl (27/150 vs 08/150 OR=3.90, p =0.0006) and blood
pressure >130/85 (74/150 vs 24/150 OR=5.11, P=0.0005) in psoriasis
patients than controls.
In all age groups they observed higher prevalence of metabolic
syndrome among cases than controls. They also observed an early onset
of metabolic syndrome in psoriasis. Comparative prevelance of metabolic
syndrome among different age groups of cases and controls is shown
below:
Such an association prompts us to look upon atherosclerotic and
psoriatic plaques as closely related entity but the conclusion awaits
establishment of a common or at least closely related etiopathogenetic
mechanism (25).
Though few studies have directly evaluated the prevalence of
metabolic syndrome in patients with psoriasis(59), various studies have
evaluated the prevalence of individual components of this syndrome (13).
OBESITY
Obesity  is  defined  as  a  body  mass  index  (BMI)  ? 30·0,  while
overweight is defined as a BMI of 25·0-29·9(22,30,60,61).  BMI  can  be
calculated by weight in kilograms divided by the square of the height in
metres(22,60,62). Both obesity and overweight are associated with increased
mortality. Body mass index(BMI) is a simple and commonly used index
to find out obesity in adults(22,60).
In addition to the well-known associations between obesity and
diabetes, hypertension, dyslipidemia, sleep apnoea, coronary heart
disease and stroke, it has also been associated with psoriasis(22).Various
studies have demonstrated that psoriasis patients are at risk of developing
obesity.(12,13,39,57,63,64,65,66,67)
The association between psoriasis and obesity make psoriasis an
important healthcare issue (43). Furthermore obesity has been shown to be
an independent risk factor for the development of psoriasis, and it is
associated with severe disease(13). Psoriatic patients from urban areas and
alcoholics are at the increased risk of obesity(68).
In a study conducted at U.K., among the 44,164  psoriasis cohort,
2760 (6·3%) patients had obesity and among the 2,19,784  comparison
cohort, 11,996 (5·5%) had  obesity. This study also says that psoriasis
patients are 1.18 times increased risk of getting obesity when compared to
controls(50).
In a study conducted at Israel, with 16,851 psoriasis patients and
48,681 controls, obesity was seen in 8.4% of patients and 3.6% of
controls (p<0.001)(69).
DYSLIPIDEMIA
Several cross-sectional and case control studies demonstrate an
association of psoriasis and dyslipidemia.(63,64,70,71)
Dyslipidemia is defined by presence of one or more abnormal
serum lipid concentration. According to NCEP-ATP III Guidelines,
hypercholesterolemia is defined as total cholesterol >200mg/dl, LDL as
>100mg/dl, hypertriglyceridemia as TGL >150mg/dl and HDL
<40mg/dl(72,73).
In a study conducted at U.K., among the 44,164  psoriasis cohort,
1900 (4·3%) patients  had  hyperlipidemia  and  among  the  2,19,784
comparison cohort, 8111 (3·7%)  had  hyperlipidemia. According to this
study psoriasis patients are 1.17 times more prone for hyperlipidemia
when compared to controls(50).
In a hospital clinic based cross-sectional study in Iran, psoriasis
patients (mean BSA 42%) were shown to have significantly higher mean
levels of triglycerides, total cholesterol, LDL and VLDL but no alteration
in HDL(74). Another study conducted by Zari Javidi et.al., also supported
the same(75).
A cross-sectional study of 84 psoriatic patients attending an
outpatient hospital based clinic in Turkey compared with 40 age and sex
matched healthy controls from the community demonstrated an higher
mean total cholesterol, triglycerides, and LDL in  the psoriasis patients
than controls(76)
A study was done in Hyderabad with 79 psoriasis patients and 79
controls, to analyse the lipid profile in psoriasis patients having less than
30% Body surface area involvement. It stated that serum cholesterol,
triglycerides and LDL cholesterol were significantly higher in psoriasis
patients and there was no significant statistical difference between VLDL
and HDL between patients and control group(77).
Various studies have failed to find consistent associations of
psoriasis with dyslipidemia. A cross-sectional study of 30 psoriasis
patients (mean PASI 10.0) attending a hospital based outpatient clinic in
Iran compared with 30 sex, age, and BMI matched healthy controls found
no association between psoriasis and alteration in fasting blood sugar,
triglycerides, total cholesterol, LDL, HDL and VLDL (78).
In addition, a case-control study of 200 recent onset predominantly
mild psoriasis patients attending a dermatology clinic in Stockholm and
285 community based controls supports the concept that lipid
abnormalities in psoriasis may be genetically determined rather than
acquired (79) .
HYPERTENSION
Hypertension, defined as a blood pressure of  > 140/90 mmHg, is
extremely common worldwide(22,80).
When Hypertension is suspected, Blood pressure should be
measured atleast twice during 2 separate examinations after the initial
screening. If the average of  >2  readings  is  >140/90mmHg  then the
patient is considered as Hypertensive(81,82). The level of systolic pressure
is more  important to assess the influence of arterial pressure on
cardiovascular morbidity(81).
Studies states that cardiovascular risk begins at a blood pressure of
>115/75 mmHg and doubles with each increment of 20/10 mmHg. The
higher the blood pressure, the greater is the risk of stroke, myocardial
infarction, heart failure and kidney failure. Clinical trials have shown that
treatment of hypertension lowers the risk of developing  heart failure by
more than 50%, risk of stroke by 35-40%, risk of myocardial infarction
by 20-25%. Current treatment guidelines suggest that treatment can be
initiated when the blood pressure is ? 140/90 mmHg for nondiabetics and
? 130/80 for those with diabetes or renal disease(22).
Several studies have demonstrated increased risk of hypertension in
psoriasis(13,18,19,57,63,70,83,84) and it occurs more commonly in alcoholics and
smokers(68).
In a study conducted at U.K., among the 44,164  psoriasis cohort,
2765 (6·3%) patients had  hypertension and  among the 2,19,784
comparison cohort, 12,754 (5·8%) had hypertension. According to this
study psoriasis patients are 1.09 times more prone for hypertension when
compared to controls(50).
In a study conducted at Israel, with 16,851 psoriasis patients and
48,681 controls it is found that hypertension was present in 27.5% of
patients and 14.4% of controls (p<0.001) (69).
DIABETES MELLITUS
The National Diabetes Data group and World Health Organization
diagnostic criteria for Diabetes mellitus is as follows:
Criteria for the diagnosis of Diabetes mellitus :
Symptoms of diabetes plus random blood glucose
concentration > 11.1 mmol/L (200 mg / dl)
or
Fasting plasma glucose > 7.0 mmol/L (126 mg / dl)
or
Two-hour plasma glucose > 11.1 mmol/L (200 mg / dl) during an
oral glucose tolerance test.
The revised criteria for diagnosis emphasize that the  Fasting
plasma glucose is a reliable and convenient test for diagnosing Diabetes
mellitus in asymptomatic individuals. A random plasma glucose
concentration > 11.1 mmol/L accompanied by classic symptoms of
diabetes mellitus (polyuria, polydipsia, weight loss) is sufficient for the
diagnosis of diabetes mellitus. Oral glucose tolerance testing, though still
a valid mechanism for diagnosing Diabetes mellitus, is not recommended
as a part of routine care(85).
When compared to national estimates, psoriatic patients have
increased risk of diabetes mellitus, hypertension, heart disease and
emphysema(19).
Many cross-sectional and case control studies have observed
an increased prevalence of diabetes in patients with
psoriasis. (45,62,63,64,70,84,86,87,88,89,90,91) Diabetes mellitus was common in
psoriasis patients aged above 40 years(88) and statistically significant
associations between psoriasis severity and markers of insulin resistance
(insulin secretion and serum resistin) was found(92).
A cross sectional study was done in Israel, to know the association
between psoriasis and metabolic syndrome. It demonstrated that psoriasis
was associated with diabetes, hypertension etc. after adjusting for age,
gender, smoking with odds ratio and 95% confidence interval as
follows(69).
Disease Odds ratio 95% confidence Interval
1. Diabetes 1.2 1-1.3
2. Hypertension 1.3 1.2-1.5
3. Metabolic syndrome 1.3 1.1-1.4
4. Obesity 1.7 1.5-1.9
5. Ischaemic heart disease 1.1 1.0-1.2
In a study conducted at U.K., among the 44,164  psoriasis cohort,
1198 (2·7%) patients  had  diabetes and among the 2,19,784  comparison
cohort, 4482 (2·0%) had diabetes. This study states that psoriasis patients
are 1.33 times more prone for diabetes mellitus when compared to
controls(50).
The risk of diabetes mellitus was high with increased severity(63)
and duration of psoriasis(26). The increased incidence in severe disease
may be due the use of very potent topical steroids or systemic
medications for psoriasis(45).
GASTRO ESOPHAGEAL REFLUX DISEASE
Obesity is common in psoriasis and this is implicated as a risk
factor for Gastro esophageal reflex disease and colorectal carcinoma(93).
INFLAMMATORY BOWEL DISEASE
The prevalence of  both crohn’s disease and ulcerative colitis are
significantly higher in Psoriasis (94). The family history of psoriasis is
frequently observed in patients with crohn’s disease(20).
NAFLD (NON – ALCOHOLIC FATTY LIVER DISEASE)
Non-alcoholic fatty liver disease (NAFLD) encompasses
conditions ranging from simple fatty liver  to non-alcoholic
steatohepatitis (NASH), which can finally give rise to fibrosis and
cirrhosis. NAFLD is mainly due to an underlying insulin-resistant state
which is a feature of the metabolic syndrome. As metabolic syndrome is
found to be associated with both psoriasis and NAFLD, it is likely that
both entities can coexist in the same patient. It is found that psoriatic
patients with NAFLD are more likely to develop progressive liver disease
such as NASH and fibrosis.
An increase in the visceral adipose tissue seen in psoriatic patients
results in the release of multiple factors such as free fatty acids, hormones
and adipocytokines which in turn lead to the development of
inflammation, insulin resistance  and  NAFLD.
NAFLD as such can also cause the release of mediators such as
reactive oxygen species , C-reactive protein, interleukin (IL)-6  and other
proinflammatory cytokines from the liver which in turn contribute to the
severity of psoriasis(95).  Imaging techniques such as USG, CT and MRI
will yield alterations suggesting increased fat in the liver(96).
It is frequently seen  in patients with chronic plaque psoriasis,
affecting upto nearly half of these patients and is strongly associated with
psoriasis severity (14). NAFLD in psoriasis patients have  significant
correlation with metabolic syndrome, obesity, hypercholesterolemia,
hypertriglyceridemia, AST/ALT >1 and psoriatic arthritis. So early
recognition of NAFLD by radiological imaging tests in this group of
patients is warranted especially when potentially hepatotoxic drug
therapy is being considered(97).
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
The prevalence of COPD is significantly higher in psoriasis and it
is also associated with metabolic syndrome. Therefore it is important to
advise them to stop smoking, to reduce the additional risk factors of
COPD(98).
DEPRESSION AND QUALITY OF LIFE IN PSORIASIS
Psoriatic patients suffer from Psychological distress especially as a
result of stigmatization, self consciousness and embarrassment,  which
inturn affect their employment and social activities. Relatively higher
rates of depression is reported in psoriasis(9,28).  Adjustment disorder and
dysthymia have also been reported (99) and it seems that patients
complaining of pruritis frequently have anxiety disorder.  Social and
occupational functioning worsened with increasing severity of psoriasis
after one year duration of illness(100).
MALIGNANCY
Patients with psoriasis are at risk of developing malignancy,
particularly non- melanoma skin cancer and lymphoproliferative
cancers(9).The risk is greater in severe disease and it probably reflects
those treated with systemic agents and phototherapy(20).
AIM OF THE STUDY
1. To find out the comorbidities that occur in psoriasis
2. To study the prevalence of these comorbidities
3. To correlate the comobidities with clinical parameters like age, sex,
duration of disease, type of psoriasis and severity.
MATERIALS AND METHODS
Study design
Descriptive study
Study centre
Department of  Dermatology and Leprosy, Rajiv Gandhi
Government General Hospital, Chennai
Study period
October 2009 to September 2011 (2 years)
Inclusion criteria
Cases of psoriasis proven by clinical examination or by biopsy
Exclusion criteria
? Patients on systemic management for psoriasis
? Patients  who were not willing to undergo investigations as per the
study protocol
Sample size
? A total of 171 patients were included in the study
? All patients were explained about the disease and the benefits of
being participating in this study.
? Consent was obtained from all the patients for participating in this
study.  For children consent was obtained from their parents.
Data collection
It was done as per the proforma.
All patients were evaluated as follows:
1. History
2. General examination
3. Systemic examination
4. Dermatological examination
5. Investigations
6. Speacialist opinions
History
The detailed history about the patients and regarding their disease
were collected. Importance was given to the particulars like
1. Age
2. Sex
3. Duration of disease
4. Area of  skin involved
5. History of  comorbidities like Diabetes mellitus,
Hypertension etc.,
6. History of comorbidities in their family
7. History of alcoholism
8. Treatment history
General  Examination
? A complete and thorough examination was done in all patients.
? Blood pressure was recorded.
? Waist circumference  was measured in cm in all, at the level of
iliac crest with the tape snuggly fitting on the skin and it was
recorded.
? Height  and weight of the patients were measured and recorded.
? Body mass index (BMI) was calculated using the following
formula: Weight (kg)  /  Height (m2)
Systemic Examination
The following systems were examined:
? Cardiovascular System
? Respiratory System
? Abdomen
? Central nervous System
Dermatological Examination
A thorough  examination of  skin lesions were done
I. To identify the type of  psoriasis
II. To assess the severity by PASI(Psoriasis Area Severity Index)
score
PASI  score
Severity of  Erythema (E), Desquamation (D) and Induration (I)
was recorded on a 5 point scale as follows:
0 -  Nil
1 -  Mild
2 - Moderate
3 - Severe
4 - Very Severe
The area of involment was recorded on a 7 point scale as follows:
0 - Nil
1 - <10%
2 - 10% - 29%
3 - 30% -  49%
4 - 50% -  69%
5 - 70% -  89%
6 - 90% -  100%
PASI was calculated as follows
PASI = 0.1(EH+IH+DH)AH +0.2 (EU+IU+DU)AU +
     0.3 (ET+IT+DT)AT +0.4 (EL+IL+DL)AL
      A   -  Area
      H   -  Head
      U    -  Upper Limb
      T    -  Trunk
      L    -  Lower Limb
Those patients whose PASI >10, erythrodermic and pustular
psoriasis were  considered to have severe disease.
Investigations
The Fasting blood sample was obtained from all the participants
for the estimation of the following parameters:
1. Fasting plasma glucose
2. Serum Cholesterol
3. Serum Triglycerides
4. Serum High density lipoprotein (HDL)
5. Serum Low density lipoprotein(LDL)
In addition,  Electrocardiogram,
Ultrasonogram abdomen,
Chest X-ray were taken in all the participants.
Other investigations like
Complete blood counts,
Liver function tests,
Renal function tests were done for treatment purpose.
Specialist Opinions
If there were  any abnormality in the above parameters, concerned
specialist opinion like
Diabetologist opinion
Medical opinion
Cardiologist opinion
Gastroenterologist  opinion etc., were sought and the instructions
were followed.
Analysis
It was done using statistical package for social sciences (SPSS)
version 16.0
OBSERVATIONS AND RESULTS
Comorbidities
Among the total 171 patients studied 123 (71.93%) patients were
having comorbidities (Fig.1)
Number of comorbidities (Fig.2)
? One comorbidity was seen in 82 patients (47.95%)
? Two comorbidities were seen in 25 patients (14.62%)
? More than two comorbities were seen in 16 patients (9.36%)
Dyslipidemia was the major component in those with 2
comorbidities. This was observed in combination with hypertension
commonly, followed by myocardial infarction, diabetes mellitus and
obesity in the order of frequency.
Most of the patients with more than two comorbidities had
metabolic syndrome.
Various comorbidities (Fig.3)
The comorbidities seen in our study were as follows:
Comorbidities
Number of patients
Percentage
Total Comorbidities
Hypertension(HT) 171 26 15.20%
Obesity(OB) 171 11 6.43%
Diabetes mellitus(DM) 171 16 9.36%
Dyslipidemia(DYS) 171 112 65.50%
Metabolic syndrome(MS) 171 15 8.77%
Myocardial infarction(MI) 171 8 4.68%
Age distribution (Fig.4)
The age of psoriatic patients having comorbidities varies from 10
to 70 years and the distribution was as shown in the table below
Age in
years
Number of  patients
Comorbidities Percentage
Total Comorbidities
1-10 5 2 DYS 40%
11-20 22 14 DYS 63.64%
21-30 30 19 DYS, HT, OB, DM 63.33%
31-40 35 26 DYS, OB, DM, MS, HT 74.29%
41-50 33 27 DYS, HT, MS, MI, OB, DM 81.82%
51-60 32 25 DYS, HT, DM, MS, OB, MI 78.13%
> 60 14 10 DYS, HT, MS, DM, MI 90.91%
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Sex distribution (Fig.5)
Male patients outnumbered the female patients in this study and the
distribution was as shown in the table
Sex
Number of  patients
Comorbidities Percentage p-value
Total Comorbidities
Males 107 74 DYS,
HT,MS,DM,
MI,OB
69.16%
0.2987
Females 64 49 76.56%
Duration of disease (Fig.6)
Duration of psoriasis in patients having comorbidities varies from 10
days to 26 years.
Duration in years
Number of patients
Percentage p-value
Total Comorbidities
Upto 5 143 100 69.93%
0.1887
Above 5 28 23 82.14%
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History of comorbidities
Only 17 (9.94%) of our patients were diagnosed to have
comorbidities while presenting to us of whom 7 (4.09%)  had developed
comorbidities before psoriasis. Among them 5 patients were prescribed ?
blockers and ACE inhibitors for their comorbidities (Hypertension). As
these drugs were supposed to precipitate or aggravate psoriasis,
alternative drugs were prescribed for them.
27 patients gave history of one or other comorbidities running in
their family. They gave history that diabetes mellitus, hypertension,
myocardial infarction were running in their families but not dyslipdemia
or obesity. 24 among these 27 patients had comorbidities. Most of them
had different comorbidities when compared to their family members.
Type of disease (Fig.7)
Comorbidities seen in each type of psoriasis is given in the table.
Type
Number of  patients
Comorbidities Percentage
Total Comorbidities
Psoriasis Vulgaris
(PASI <10)
40 26
DYS,HT,MS,
DM,MI
65%
Psoriasis Vulgaris
(PASI >10)
40 34
DYS,HT,DM,
MS,OB,MI
85%
Palmoplantar
psoriasis
35 26
DYS,HT,MS,
DM,OB
74.29%
Erythrodermic
psoriasis
20 9
DYS,DM,MI,
OB,HT,MS
45%
Pustular psoriasis 14 11
DYS,HT,MS,
DM,OB,MI
78.5%
Guttate psoriasis 22 17 DYS,OB 77.27%
Severity (Fig.8)
The distribution of comorbidities with respect to severity of the
disease is given here.
Severity
Number of patients
Percentage p-value
Total Comorbidities
Mild or
Moderate
94 66 70.21%
0.5809
Severe 77 57 74.02%
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HYPERTENSION
This was present in 26(15.2%)  out of 171 patients.
Their age distribution(Fig.9) varies from 29 to 70 years. 2 of the
patients in the group of  upto 40 years, were of age 29 and 40.
Age in years
Number of patients
Percentage p-value
Total Hypertension
Upto 40 92 2 2.17%
<0.001
Above 40 79 24 30.38%
Sex distribution(Fig.10) of  patients with hypertension was shown
in the table below
Sex
Number of patients
Percentage p-value
Total Hypertension
Males 107 15 14.01%
0.5765
Females 64 11 17.18%
Duration of psoriasis in patients with hypertension varies from 1
month to 20 years and it is shown in figure 11.
Hypertension is seen in palmoplantar psoriasis , psoriasis vulgaris,
pustular type, erythrodermic psoriasis in the decreasing order of
frequency. The distribution (Fig. 12) is given here
Type
Number of patients
Percentage
Total Hypertension
Psoriasis Vulgaris (PASI <10) 40 7 17.50%
Psoriasis Vulgaris (PASI >10) 40 8 20%
Palmoplantar psoriasis 35 8 22.85%
Erythrodermic psoriasis 20 1 5%
Pustular psoriasis 14 2 14.28%
Guttate psoriasis 22 0 0%
Severity of  the disease in patients with hypertension is given here.
Severity
Number of patients
Percentage p-value
Total Hypertension
Mild or Moderate 94 15 15.95%
0.3810
Severe 77 11 14.28%
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OBESITY
This was present in 11(6.43%) out of 171patients.
Their age distribution (Fig.13) was from 28 to 56 years.
Age in years
Number of patients
Percentage p-value
Total Obesity
Upto 40 92 4 4.35%
0.2310
Above 40 79 7 8.86%
Sex distribution (Fig.14)  of patients having obesity was shown
below
Sex
Number of patients
Percentage p-value
Total Obesity
Males 107 7 6.54%
0.9390
Females 64 4 6.25%
Duration of psoriasis in them varies from 1 month to 20 years and
it is shown in  figure 15.
Obesity  is  common in erythrodermic psoriasis followed by guttate
psoriasis,  psoriasis vulgaris (PASI >10), pustular type, palmoplantar
psoriasis, psoriasis vulgaris (PASI <10) in the decreasing order of
frequency. The distribution (Fig.16)  is shown below.
Type
Number of patients
Percentage
Total Obesity
Psoriasis Vulgaris (PASI <10) 40 1 2.5%
Psoriasis Vulgaris (PASI >10) 40 3 7.5%
Palmoplantar psoriasis 35 2 5.71%
Erythrodermic psoriasis 20 2 10%
Pustular psoriasis 14 1 7.14%
Guttate psoriasis 22 2 9.09%
Severity of psoriasis in obese patients is given below
Severity
Number of patients
Percentage p-value
Total Obesity
Mild or  Moderate 94 5 5.31%
0.256
Severe 77 6 7.79%
In addition  29(16.96%) patients were preobese who were at risk of
developing obesity in future. Their age varies from 13 to 62 years.
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DIABETES MELLITUS
This was present in 16(9.34%) out of 171 patients.
Their age distribution (Fig.17)  varies from 29 to 70 years
Age in years
Number of patients
Percentage p-value
Total Diabetes mellitus
Upto 40 92 4 4.35%
0.0152
Above 40 79 12 15.19%
Their sex distribution (Fig.18)  was given in the table
Sex
Number of patients
Percentage p-value
Total Diabetes mellitus
Males 107 12 11.21%
0.2819
Females 64 4 6.25%
Duration of psoriasis in diabetes varies from 2 months to 26 years
and it is given in figure 19.
It is common in psoriasis vulgaris (PASI>10). It was also observed
in other types as shown in the table below and  figure 20.
Type
Number of patients
Percentage
Total Diabetes mellitus
Psoriasis Vulgaris (PASI <10) 40 4 10%
Psoriasis Vulgaris (PASI >10) 40 6 15%
Palmoplantar psoriasis 35 1 2.85%
Erythrodermic psoriasis 20 3 15%
Pustular psoriasis 14 2 14.28%
Guttate psoriasis 22 0 0%
Severity of psoriasis in diabetic patients is given below
Severity
Number of patients
Percentage p-value
Total Diabetes mellitus
Mild or Moderate 94 5 5.31%
0.0451
Severe 77 11 14.28%
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DYSLIPIDEMIA
This was present in 112(65.5%) out of 171 patients.
Their age distribution (Fig.21)  varies from 10 to 70 years and it
was given in the table below
Age in years
Number of patients
Percentage
Total Dyslipidemia
1-10 5 2 40%
11-20 22 12 54.5%
21-30 30 20 66.66%
31-40 35 23 65.71%
41-50 33 24 72.72%
51-60 32 22 68.75%
>60 14 9 64.28%
Sex distribution (Fig.22)  of patients with dyslipidemia was given
here.
Sex
Number of patients
Percentage p-value
Total Dyslipidemia
Males 107 67 62.61%
0.3075
Females 64 45 70.31%
Duration of  psoriasis varies from 10 days to 20 years in patients
having Dyslipidemia and it is given in figure 23.
It is common in pustular psoriasis but noted in other types too as
given below and figure 24.
Type
Number of patients
Percentage
Total Dyslipidemia
Psoriasis Vulgaris (PASI <10) 40 25 62.5%
Psoriasis Vulgaris (PASI >10) 40 28 70%
Palmoplantar psoriasis 35 24 68.57%
Erythrodermic psoriasis 20 7 35%
Pustular psoriasis 14 11 78.57%
Guttate psoriasis 22 17 77.27%
Distribution of  dyslipidemia with respect to severity of  psoriasis
is given here
Severity
Number of patients
Percentage p-value
Total Comorbidities
Mild or Moderate 94 63 67.02%
0.6432
Severe 77 49 63.63%
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METABOLIC SYNDROME
This was present in 15(8.77%) out of 171 patients.
Their age distribution (Fig. 25)  varies from 33 to 70 years
Age in years
Number of patients
Percentage p-value
Total Metabolic syndrome
Upto 40 92 2 2.17%
0.001
Above 40 79 13 16.45%
The sex distribution (Fig. 26)   of these patients was shown in the
table
Sex
Number of patients
Percentage p-value
Total Metabolic syndrome
Males 107 8 7.47%
0.4388
Females 64 7 10.94%
      Duration of psoriasis in them varies from 1 month to 10 years and it is
shown in figure 27.
This  is seen in erythrodermic psoriasis, palmoplantar psoriasis,
psoriasis vulgaris (PASI >10), psoriasis vulgaris (PASI <10) and pustular
types in increasing order of frequency. This is shown in  figure 28 to 32.
Type
Number of patients
Percentage
Total Metabolic
syndrome
Psoriasis vulgaris (PASI <10) 40 5 12.5%
Psoriasis vulgaris (PASI >10) 40 4 10%
Palmoplantar psoriasis 35 3 8.57%
Erythrodermic psoriasis 20 1 5%
Pustular psoriasis 14 2 14.28%
Guttate psoriasis 22 0 0%
Patients with metabolic syndrome had severity of psoriasis as
follows
Severity
Number of patients
Percentage p-valueTotal Comorbidities
Mild or  Moderate 94 8 8.51%
0.894
Severe 77 7 9.09%
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Figure 29
Psoriasis vulgaris of mild type in a male
with waist circumference of 116 cm
Figure 30
Psoriasis vulgaris of severe type in a male
with waist circumference of 109 cm
Figure 31
Psoriasis vulgaris of severe type in a female
with waist circumference of 94 cm
Figure 32
Psoriatic erythroderma in a male with
waist circumference of 113 cm
MYOCARDIAL INFARCTION
      This was present in 8(4.68%) out of 171 patients. They had
anteroseptal myocardial infarction or inferior wall myocardial infarction
or unstable angina. Their ECGs are shown in figure 33 to 35.
      Their age distribution was from 44 to 67 years
Age in years
Number of patients
Percentage p-value
Total Myocardial infarction
Upto 40 92 Nil 0%
0.002
Above 40 79 8 10.13%
Their sex distribution (Fig. 36) was given below in the table
Sex
Number of patients
Percentage p-value
Total Myocardial infarction
Males 107 7 6.54%
0.1357
Females 64 1 1.56%
Duration of psoriasis in them varies from 1to 19 years and it is
shown in figure 37.
It is seen in psoriasis vulgaris, pustular psoriasis and erythrodermic
type in increasing order of frequency and this is given in figure 38.
Type
Number of patients
Percentage
Total
Myocardial
infarction
Psoriasis Vulgaris (PASI <10) 40 2 5%
Psoriasis Vulgaris (PASI >10) 40 2 5%
Palmoplantar psoriasis 35 0 0%
Erythrodermic psoriasis 20 3 15%
Pustular psoriasis 14 1 7.14%
Guttate psoriasis 22 0 0%
Distribution of myocardial infarction with respect to severity of
psoriasis is shown here.
Severity
Number of patients
Percentage p-value
Total Myocardial infarction
Mild - Moderate 94 2 2.12%
0.0810
Severe 77 6 7.79%
Figure 33
ECG of psoriasis vulgaris patient with anteroseptal myocardial infarction
Figure 34
ECG of psoriatic erythroderma patient with inferior wall myocardial infarction
Figure 35
ECG of psoriasis vulgaris patient with unstable angina
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FATTY LIVER DISEASE
This was seen in 44(25.73%) of our patients. Males(30 patients)
outnumbered the females(14 patients) and half of the males were
alcoholics.
DEPRESSION
One of our patient had depression which had simultaneous onset
with psoriasis.
PERIPHERAL VASCULAR DISEASE (Figure 39)
Two of our patients had peripheral vascular disease. It occurred
before the onset of psoriasis in one patient (duration of  peripheral
vascular disease -15 years, duration of psoriasis – 13 years)
Figure 39
Psoriasis vulgaris patient having autoamputation of left 2nd toe
following peripheral vascular disease
Figure 40
Histopathology of the patient with psoriasis vulgaris
DISCUSSION
In the present era, psoriasis is emerging as an important skin
disease associated with various comorbidities. These comorbidities are
associated with increased risk of morbidity and mortality. The chronic
inflammatory nature of  psoriasis is responsible for the occurance of
comorbidities and TNF ? plays a central role in this. Several studies have
documented its occurrence in psoriasis. We designed this study to
highlight the association of common clinical types of psoriasis and
comorbidities.
Comorbidities:
Comorbidities were seen in 71.93%(123/171) of psoriasis patients
in our study. Like previous studies, the major comorbidities observed in
our study were Hypertension,(50,69) Obesity,(50,69) Diabetes
mellitus,(19,26,50,63) Dyslipidemia,(50,74-79) Metabolic syndrome,(25,56,57)
Myocardial infarction.(24,36-38)  In  addition  to  the  above  few of  them had
fatty liver disease, depression and peripheral  vascular disease.
Most of the patients had one comorbidity (47.95%) followed by
two in some and more than two comorbidities in few patients.
Dyslipidemia (65.5%) was the commonest comorbidity in our study
followed by Hypertension (15.2%), Diabetes mellitus (9.34%), Metabolic
syndrome (8.77%), Obesity (6.43%), Myocardial infarction (4.68%).
A study conducted by Jayakar Thomas et.al., at Tamilnadu, stated that
obesity was seen in 6.6% of psoriatics(21). Another study by J.A. Kaye
et.al, at U.K, also said 6.3% of psoriatics were obese.(50)
Age and comorbidities:
Most of the patients with comorbidites were in the age group of 31
to 70 years. To our surprise we noticed dyslipidemia in those aged
between 10 to 20 years in our study. It was the only comorbidity observed
in them. So we suggest that dyslipidemia can occur at any age from 10
years onwards. The study by M.Augustin  et al., supports our concept.(3)
Statistically significant proportion of patients with hypertension,
diabetes mellitus, metabolic syndrome, myocardial infarction were aged
above 40 years. The respective p-values are <0.001, 0.0152, 0.001, 0.002.
A study conducted previously by Gisondi et.al., supports our concept of
occurance of metabolic syndrome in those aged above 40 years(57).
Dyslipidemia and obesity were seen at younger age in our study
and this is supported  by the study by M.Augustin  et al., at Germany(3).
Since dyslipidemia and  obesity are the risk factors for myocardial
infarction, young psoriasis patients are more likely to have myocardial
infarction as stated in the previous studies. (35,39,40,41)
Gender and comorbidities:
Both males and females had comorbidities and there was no
statistically significant difference in occurance of comorbidities between
them (p-value: 0.2987). All comorbidities observed in this study were
seen in both the sexes. A study carried out by Gisondi et.al., also stated
the metabolic syndrome can affect both sexes(57), and this supports our
results.
Duration of psoriasis and comorbidities:
Duration of psoriasis in patient with comorbidities varies widely in
our study.There was no significant difference in the occurance of
comorbidities in those having the disease for upto 5 years and  above 5
years (p-value: 0.1887). Although few studies have mentioned that
comorbidities were frequent with increase in duration of psoriasis(26) this
was not noted in our study.
History of comorbidities:
Only 9.94% of our patients were aware that they had comorbidities
while presenting to us and few of them were already on treatment with
drugs which may  aggravate psoriasis. This stresses the importance of
awareness of side effects and interaction of drugs. Few of our patients
gave history of comorbidies in their family members irrespective of their
current comorbidity.
Type of psoriasis and comorbidities:
Comorbidities were commonly seen in psoriasis vulgaris of severe
type (85%) in our study followed by pustular psoriasis (78.5%), guttate
psoriasis (77.27%), palmoplantar psoriasis (74.29%), psoriasis vulgaris of
mild to moderate type (65%) and erythrodermic type(45%).
All the 6 comorbidities mentioned above were seen in psoriasis
vulgaris, erythrodermic and pustular type, while dylipidemia and obesity
were the only observed comorbidity in guttate psoriasis and myocardial
infarction was not observed in palmoplantar psoriasis in our study.
In our study hypertension was common in palmoplantar type.
Obesity,  diabetes mellitus, myocardial infarction were common in
psoriatic erythroderma. Dyslipidemia and metabolic syndrome were
observed commonly in pustular psoriasis. The prevalence of
comorbidities in common types is shown below:
S.No. Comorbidities Type of psoriasis
1. Hypertension Palmo plantar psoriasis - 22.86%
Psoriasis vulgaris(PASI >10) – 20%
2. Obesity Psoriatic erythroderma – 10%
Guttate psoriasis – 9.09%
3. Diabetes mellitus Psoriatic erythroderma – 15%
Psoriasis vulgaris(PASI >10) – 15%
Pustular psoriasis – 14.28%
4. Dyslipidemia Pustular psoriasis – 78.57%
Guttate psoriasis – 77.27%
5. Metabolic syndrome Pustular psoriasis – 14.28%
Psoriasis vulgaris(PASI <10) – 12.5%
6. Myocardial
infarction
Psoriatic erythroderma – 15%
Pustular psoriasis – 7.14%
        This reveals that any comorbidities can occur in any type of
psoriasis. Hence detection and treatment of comorbidies is needed in all
types of psoriasis.
Severity of psoriasis and comorbidities:
Few of the previous literature reports stated that comorbidities are
common in severe disease.(13,45,63) But in our study, though  comorbidities
were commonly present  in severe disease, it was also seen in mild type
of psoriasis vulgaris and palmoplantar types.
Although slightly more number of patients with comorbidities had
severe disease (Mild or moderate – 70.21% Vs Severe – 74.02%) it is not
statistically significant (p-value: 0.5809). This states that comorbities can
occur in psoriasis irrespective of its severity.
Diabetes mellitus was the only comorbidity in which statistically
significant number of  patients had severe disease (p-value: 0.0451). The
study by Neimann AL, Shin DB, Wang X, et al., at U.K., supports this
concept.(63)
Except diabetes mellitus all other comorbidities were present
irrespective of severity of psoriasis. Previously Gisondi et al., and
Takahashi et al., said that there was no correlation  between  severity of
psoriasis and metabolic syndrome.(56) This study supports our results.
CONCLUSION
? Comorbidities in psoriasis is common and its prevalence is 71.93%
in our study.
? The comorbidities observed in our study in the decreasing order of
frequency are dyslipidemia, hypertension, diabetes mellitus,
metabolic syndrome, obesity, myocardial infarction.
? Hypertension, diabetes mellitus, metabolic syndrome, myocardial
infarction are common in those aged above 40 years while
dyslipidemia and obesity are present in younger age.
? Both sexes had all the comorbidities and there is no statistically
significant difference in its occurrence with respect to psoriasis
duration or severity.
? Comorbidities are common in psoriasis vulgaris of severe type.
They are also seen in psoriasis vulgaris of mild or moderate type,
psoriatic erythroderma, guttate type, pustular and palmoplantar
psoriasis.
? Our study states that psoriasis is emerging  as a systemic disease in
current days and it is not just skin deep.
? As Dermatologists we should be aware of these comorbidities since
we have the unique opportunity to screen, identify and followup
the comorbidities in psoriasis.
? So we strongly recommends screening for comorbidities in all
patients with psoriasis, irrespective of their age, sex, duration of
disease, severity and type of psoriasis.
? Even if comorbidities are not detected at screening, adapting
healthy life style practices are highly needed from the time of
diagnosis in present era to prevent these comorbidities.
? We would like to conclude that treatment of psoriasis successfully
with a improvement in quality of life patients could be achived
with unified management by dermatologists and other specialists.
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PROFORMA
S. No.: OP. No.:                          Psoriasis Clinic No.:
Name: Age:           Sex:
Occupation:
Address : Rural / Urban                                            Phone no.:
PRESENTING COMPLAINTS
HISTORY OF PRESENT ILLNESS
Evolution of disease:
H/O Itching:
H/O Sore throat:
H/O Drug intake:
H/O Seasonal variation:
H/O Remission and exacerbation:
H/O Trauma and surgeries:
H/O Joint Pain and swelling:
H/O Photosensitivity:
H/S/O diabetes or hypertension:
H/S/O cardiac diseases:
H/S/O respiratory diseases:
H/S/O gastrointestinal diseases:
H/S/O renal diseases:
H/S/O cerebrovascular disease:
H/O loss of weight and loss of appetite:
PAST HISTORY
H/O Similar illness:
Myocardial infarction / Psychiatric illness
Other illness:
FAMILY HISTORY
Psoriasis:
Comorbidities:
PERSONAL HISTORY
Alcoholism:                                                                            Smoking:
MENSTRUAL AND OBSTETRIC HISTORY IN FEMALES
TREATMENT HISTORY
Psoriasis:
Comorbidities:
GENERAL EXAMINATION
Built:                                              Nourishment:
Anaemia / Jaundice / Clubbing / Dyspnoea / Pedal edema/
Lymphadenopathy / JVP
BP:                               PR:                             Temperature:
Waist Circumferance:         Weight:   Height:                       BMI:
SYSTEMIC EXAMINATION
CVS:                                                     Abdomen:
RS:                                                     CNS:
Endocrine system:
DERMATOLOGICAL EXAMINATION
Description and extent of lesions:
Mucosa:
Hair:
Nails:
Joints ( minor and major):
Type of psoriasis :                                                            PASI score:
Severity: Mild - moderate / severe
Any other associated cutaneous diseases:
INVESTIGATIONS
1. Skin biopsy:
2. Complete blood count:  Hb% -     DC: P -         L -             E -
TC -                  Platelets -                          ESR -
3. Fasting plasma glucose:                4.Postprandial plasma glucose:
5. Lipid profile: Total Cholesterol:      Triglycerides:                       HDL:
     LDL:                                        VLDL:
6. ECG:
7. ECHO:
8.Chest X-Ray:
9.Urine:Albumin:               Sugar:                            Deposits:
10.USG Abdomen:
11. LFT : Total Bilirubin:   Total Proteins:      Albumin: Globulin:
                SGOT:                         SGPT:                        SAP:
12.HbsAg:                                            13. anti-HCV:
14.Blood urea:                                   15. Serum creatinine:
16.Serum electrolytes: 17. HIV-ELISA:
18.VDRL: 19. Serum Calcium:
20.Serum uric acid: 21. X-ray joints:
22. PT:                       23. aPTT:                        24. INR :
25.Doppler: 26.T3:                              27.T4:
28.TSH: 29. Diabetology opinion:
30. HT clinic opinion:
31.Cardiologist opinion:
32.Chest physician opinion:
33.Gastroenterology opinion:
34. Orthopaedics Opinion:
35.Vascular Surgeon opinion:
36. Neurologist opinion:
37. Psychiatry opinion:
38. Endocrinology opinion:
39. STD opinion:
40.Others:
ENT opinion
Dental opinion:
Ophthalmology opinion:
Master charts
S.No AGE SEX DD CD PASI WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
1 58 M 8 Y       - 3 107 28 79 173 110 129 37 FL N   -      -      -         -       +    -  +    -      - PRE OBESE ,?WC
2 37 M 3Y       - 4.2 74 21.1 85 142 64 131 52 N N   -      -      -         -      -    -    -      -      -    -
3 55 M 3.5Y HT-3Y 5.1 90 26.6 70 206 151 83 38 N LVH +    -      -  +     +    -  +    -      - PRE OBESE
4 22 F 1 Y       - 2 57 14.6 97 160 95 116 42 N N   -      -      -   -    -    -    -      -      -    -
5 48 M 1Y       - 1 68 17.5 76 149 89 89 42 N N   -      -      -      -    -    -    -      -      -    -
6 24 M 4Y       - 6.8 94 25.2 85 200 134 123 41 FL N   -      -      -      -       +    -    -      -      - PRE OBESE
7 28 M 5Y       - 1.2 92 30.5 73 146 90 109 34 N N   - +    -      -    -    -  +    -      -    -
8 50 M 2Y       - 5.4 82 21.7 101 142 75 145 38 FL N   -      -      -      -    -    -  +    -      -    -
9 71 M 6m       - 2 85 21.9 73 161 96 110 43 N N   -      -      -      -    -    -    -      -      -    -
10 60 F 10Y       - 1.8 86 29.7 72 242 164 219 34 FL N   -      -      -  +     +  +  +    -      - PRE OBESE
11 54 F 3Y       - 2 78 21.3 68 131 64 81 51 N N   -      -      -      -    -    -    -      -      -    -
12 57 M 1Y       - 6.4 95 25.5 98 187 90 289 39 FL N +    -      -      -    -  +  +    -      - PRE OBESE
13 59 M 5Y       - 1.2 87 23.5 110 143 89 110 32 FL UA   -      -      -      -    -    -  +    - +    -
14 64 F 5Y       - 6.9 81 21 122 205 141 84 47 N N   -      -      -  +     +    -    -      -      -    -
15 30 M 1Y       - 3.1 90 22.6 100 156 88 122 44 FL N   -      -      -      -    -    -    -      -      -    -
16 46 M 4Y       - 5 88 22 100 148 77 144 42 FL UA   -      -      -      -    -    -    -      - +    -
17 52 F 1Y       - 2.8 85 28.5 67 209 137 161 40 FL N   -      -      -  +     +  +    -      -      - PRE OBESE
18 43 M 10Y DM,HT-2Y 2.4 116 23.3 104 162 88 172 40 FL N +    - +    -    -  +    - +    - ? WC
19 42 M 4Y       - 1.5 85 25.5 95 165 109 80 40 N N   -      -      -      -       +    -    -      -      - PRE OBESE
20 70 M 4Y       - 1.6 75 24.5 206 291 240 98 31 N N +    - +  +     +    -  + +    -    -
PSORIASIS VULGARIS(PASI < 10)
S.No AGE SEX DD CD PASI WC BMI FPG  CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
21 60 F 5m      - 4.8 96 29.3 81 181 106 111 43 N N   +   -   -    -     +     -     +   +   - PRE OBESE, ?WC
22 60 F 3Y       - 2.6 83 28.5 186 200 116 237 37 RC N   -   -   +    -     +     +     +   +   - PRE OBESE
23 24 F 5Y       - 9.6 76 21.2 68 180 122 99 38 N N   -   -   -    -     +     -     +    -   -           -
24 36 M 3Y       - 5.8 68 16.8 83 153 100 76 38 N N   -   -   -    -     -     -     +    -   -           -
25 64 F 2m      - 0.4 87 21.1 279 128 76 91 34 N N   +   -   +    -     -     -     +   +   -           -
26 54 M 3m      - 2.4 99 23.3 88 310 246 108 42 N N   +   -   -    +     +     -     -    -   -           -
27 45 M 9m      - 4.2 86 23 87 135 54 174 46 N N   -   -   -    -     -     +     -    -   -           -
28 58 M 2Y       - 6.6 88 25.6 94 196 113 180 47 N N   -   -   -    -     +     +     -    -   - PRE OBESE
29 13 F 1Y       - 8.4 57 13.5 60 140 64 131 50 N N   -   -   -    -     -     -     -    -   -           -
30 12 F 4Y       - 4.2 58 16.3 86 182 111 92 53 N N   -   -   -    -     +     -     -    -   -           -
31 13 M 6Y       - 7.6 65 17.4 95 145 91 109 32 N N   -   -   -    -     -     -     +    -   -           -
32 13 M 2Y       - 1.1 57 18.1 83 150 105 75 30 N N   -   -   -    -     +     -     +    -   -           -
33 10 M 2m      - 5.9 56 15 66 146 86 112 38 N N   -   -   -    -     -     -     +    -   -           -
34 11 F 5Y       - 3.3 58 15.4 80 165 99 90 48 N N   -   -   -    -     -     -     -    -   -           -
35 6 F 4Y       - 1.8 46 13.5 84 144 73 99 51 N N   -   -   -    -     -     -     -    -   -           -
36 15 M 4Y       - 2.7 74 20 84 145 76 85 52 N N   -   -   -    -     -     -     -    -   -           -
37 21 M 2Y       - 6.8 76 21.9 96 158 89 131 43 N N   -   -   -    -     -     -     -    -   -           -
38 32 F 1Y       - 5.4 82 21.7 93 161 85 124 51 N N   -   -   -    -     -     -     -    -   -           -
39 28 M 2Y       - 2.7 78 24.2 94 171 98 128 47 N N   -   -   -    -     -     -     -    -   -           -
40 41 F 1Y       - 3.3 81 23.3 91 164 89 115 52 N N   -   -   -    -    -    -     -    -    -            -
PSORIASIS VULGARIS(PASI < 10)
S.No Age Sex DD CD PASI WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
1 27 M 4Y - 36.4 86 15 110 199 105 189 56 N N - - - - + + - - - -
2 48 M 12Y - 21.1 76 19.81 137 164 92 90 54 N N - - + - - - - - - -
3 60 M 3m - 43 99 24.77 94 148 88 105 39 N N - - - - - - + - - -
4 27 M 10Y - 30.4 82 20.05 77 192 138 88 36 N N - - - - + - + - - -
5 56 F 10Y HT-3m 12 109 33.73 167 388 328 95 41 FL N + + + + + - - + - ? WC
6 52 M 4Y DM-1Y 17.6 89 22.27 225 124 61 104 42 N N - - + - - - - - - -
7 54 M 26Y DM-5Y 10.1 79 20.2 138 144 75 81 53 N N - - + - - - - - - -
8 32 F 2Y - 12.8 77 24.1 69 238 148 269 36 N N - - - + + + + - - -
9 40 M 8Y - 13.5 94 25.34 62 185 113 160 40 N N - - - - + + - - - PRE OBESE
10 61 F 2Y - 19.8 85 19.5 70 213 135 113 55 FL N + - - + + - - - - -
11 47 M 8Y - 12.1 101 31.63 62 120 52 99 48 FL N - + - - - - - - - -
12 65 M 1.5Y - 19.5 92 20.09 69 196 128 90 50 FL N + - - - + - - - - -
13 55 M 2Y - 13 109 24.17 103 223 144 167 46 FL N + - - + + + - + - ? WC
14 61 M 2Y - 11.4 92 25.32 111 144 80 164 31 RC N - - - - - + + - - PRE OBESE
15 36 M 13Y - 10.9 76 16.6 90 130 52 110 56 N N - - - - - - - - - -
16 44 M 19Y MI,HT,PVD-3Y 13 79 18.9 84 146 59 182 51 FL ASMI + - - - - + - - + PVD
17 35 F 14Y - 13.8 63 19.98 91 225 157 96 48 N N - - - + + - - - - -
18 30 M 3Y - 12.4 75 19.47 83 156 94 99 42 N N - - - - - - - - - -
19 35 F 1m - 33 94 33.31 98 220 145 185 38 FL N - + - + + + + + - ?WC
20 35 F 5m - 22.4 79 22.59 71 189 113 117 52 FL N - - - - + - - - - -
PSORIASIS VULGARIS (PASI > 10)
S.NO Age Sex DD CD PASI WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ? CHO ? LDL ? TGL ? HDL MS MI OTHERS
21 45 M 10Y - 27.5 84 21.63 81 238 160 132 52 FL ASMI - - - + + - - - + -
22 30 F 7Y - 16.5 67 19.23 74 271 74 109 51 N N - - - + - - - - - -
23 12 M 4Y - 14.2 53 16.22 76 142 88 112 32 N N - - - - - - + - - -
24 10 F 1Y - 28.3 51 22.32 78 120 62 108 36 N N - - - - - - + - - -
25 60 M 1Y - 15.4 75 21.5 105 174 114 102 40 FL,RC N - - - - + - - - - -
26 43 M 2Y - 17.6 81 23.39 86 140 73 95 48 N N - - - - - - - - - -
27 29 M 3Y HT,DM-8m 12.4 64 24.74 107 259 196 89 45 FL N + - + + + - - - - -
28 40 F 5Y - 11.4 80 25.1 74 204 125 131 53 N N - - - + + - - - - PRE OBESE
29 38 M 4Y DM-3Y 16.8 78 21.01 110 147 63 221 40 N N - - + - - + - - - -
30 30 F 2Y - 13.5 79 24.46 70 168 105 128 37 RC N - - - - + - + - - -
31 31 M 1Y - 19.4 76 21.63 91 171 102 131 43 N N - - - - + - - - - -
32 48 F 2Y - 21.4 79 24.17 94 156 86 94 51 N N - - - - - - - - - -
33 60 M 15D - 11.4 90 19.9 97 205 139 119 42 N N - - - + + - - - - -
34 65 F 1m - 14.4 104 24.2 120 121 49 52 62 FL N - - - - - - - - - ?WC
35 57 M 1m - 14.2 67 17 52 161 96 104 44 N N - - - - - - - - - -
36 62 M 3Y - 13.2 97 26.74 63 155 89 118 42 FL ASMI + - - - - - - - + PRE OBESE
37 60 M 20Y - 12.4 72 20.32 87 175 108 130 41 N N + - - - + - - - - -
38 43 M 10Y - 11.8 107 24.3 58 189 131 90 40 FL N - - - - + - - - - ?WC
39 23 F 3Y - 22.4 66 15.56 99 158 79 174 44 FL N - - - - - + - - - -
40 33 F 13Y PVD-15Y 13.4 90 24.17 102 136 71 123 40 N N - - - - - - - + - ??WC,PVD
PSORIASIS VULGARIS(PASI >10)
S.No AGE SEX DD CD PASI WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
1 27 F 11m    - 4.8 81 19.6 82 190 117 110 51 N N - - - -    + - - - - -
2 55 M 5Y    - 2.6 82 21.23 92 153 88 93 46 N N - - - - - - - - - -
3 60 M 1Y    - 2.8 98 29.75 140 169 103 136 39 FL N - - + -    + -    + - - PRE OBESE
4 45 F 6m    - 2 58 17.12 87 162 94 75 53 N N - - - - - - - - - -
5 40 M 3Y    - 1.4 90 26.4 86 189 114 203 34 FL N - - - -    +    +     + - - PRE OBESE
6 27 F 5m    - 1.2 68 19.07 100 139 53 166 53 N N - - - - -    + - - - -
7 40 F 1m    - 2.4 76 22.37 96 140 62 110 26 N N - - - - - -    + - - -
8 45 F 2Y    - 1.8 95 24.65 98 227 134 193 54 N N - - -    +    +    + - - - -
9 56 M 2Y    - 2 95 23.31 98 241 149 221 48 FL N + - -    +    +    + - - - ?WC
10 42 F 3m    - 3.2 74 15.95 76 147 94 85 36 FL N - - - - - -    + - - -
11 50 F 1m HT-2Y 2.2 88 28.27 70 175 106 149 39 N N + - - -    + -    + - - PRE OBESE
12 36 M 4Y    - 2.8 96 29.76 97 181 115 131 40 FL N - - - -    + - - - - PRE OBESE
13 28 M 6m    - 1.6 82 22.49 80 192 120 187 35 N N - - - -    +    +     + - - -
14 29 M 6m    - 1.4 89 23.51 92 106 47 52 51 FL N - - - - - - - - - -
15 55 M 2.5m    - 2.4 81 19.82 82 165 99 89 48 N N + - - - - - - - - -
16 50 F 6m    - 2 82 19.88 105 185 120 100 45 N N - - - -    + - - - - -
17 50 F 6m    - 2.6 101 32.27 99 345 254 220 47 N N + + -    +    +    + - + - ?WC
18 58 F 1Y    - 1.6 82 24.53 70 161 82 159 47 FL N - - - - -    + - - - -
19 23 F 3m    - 2 80 29.43 80 157 97 89 42 N N - - - - - - - - - PRE OBESE
20 48 M 1Y    - 2.8 84 23.31 84 173 117 83 39 FL N - - - -    + -    + - - -
PALMOPLANTAR PSORIASIS
S.NO AGE SEX DD CD PASI WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
21 50 F 1Y    - 2 83 26.49 79 204 134 136 43 FL N   + - -    +     + - - - - PRE OBESE
22 31 F 1Y    - 2.8 108 36.26 83 163 97 118 42 FL N - + - - - - - - -   ?WC
23 35 M 6m    - 1.6 80 21.26 91 181 127 89 36 FL N - - - -    + -    + - - -
24 15 F 5Y    - 2.4 61 17.59 66 173 118 94 36 N N - - - -    + -    + - - -
25 13 M 6Y    - 3.2 57 17.33 80 126 70 80 40 N N - - - - - - - - - -
26 13 M 5m    - 4.4 82 26.03 76 141 85 100 36 N N - - - - - -    + - - PRE OBESE
27 13 M 4Y    - 1.8 56 13.94 84 166 99 94 48 N N - - - - - - - - - -
28 14 M 2m    - 1.2 56 14.13 79 126 62 111 42 N N - - - - - - - - - -
29 43 F 1Y    - 1.4 74 24.78 84 184 106 198 38 N N + - - -    +    +     + + - -
30 21 F 3Y    - 2.6 77 20.7 118 174 114 84 43 N N - - - -    + - - - - -
31 58 M 5Y    - 2.4 85 26.77 80 170 106 96 45 N N + - - -    + - - - - PRE OBESE
32 45 F 10Y HT-2m 2 89 26.48 76 221 145 216 33 N N + - -    +     +    +     + + - PRE OBESE
33 38 M 3Y    - 1.6 92 24.1 79 168 89 142 51 N N - - - - - - - - - -
34 29 M 2Y    - 1.2 89 22.21 82 171 95 132 50 N N - - - - - - - - - -
35 31 M 4Y    - 1.8 94 26.8 94 184 109 141 47 N N - - - -    + - - - - PRE OBESE
PALMOPLANTAR PSORIASIS
S.NO Age Sex DD CD WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
1 38 M 5Y     - 90 23.62 176 275 215 112 38 N N - -  +       +     + -    + - - -
2 45 F 1Y MI-5Y 75 19.67 98 168 89 152 49 N IWMI - - - - -    + - -  + -
3 65 M 1Y MI-6Y 96 22.49 70 159 109 76 35 N IWMI - - - -    + -    + -  + -
4 60 M 1m     - 94 21.34 82 165 99 95 47 RC N - - - - - - - - - -
5 38 M 1Y     - 72 18.29 71 147 89 120 34 N N - - - - - -    + - - -
6 67 M 7m     - 82 19.49 98 213 143 141 42 N N - - - +    + - - - - -
7 56 M 1.5Y     - 108 30.06 74 154 98 76 41 FL N   +     +   - - - - - - - ?WC
8 58 M 1Y     - 70 17.47 88 150 95 67 42 RC N - - - - - - - - - -
9 87 M 1Y     - 77 19.15 119 142 73 138 41 N N - - - - - - - - - -
10 40 F 18Y     - 78 22.48 82 142 83 86 42 N N - - - - - - - - - -
11 44 M 3Y     - 79 23.51 60 146 93 76 38 FL N - - - - - -    + - - -
12 47 M 4Y     - 113 30.11 135 200 133 133 40 N N -  +     + -     + - -   +   - ?WC
13 30 M 8y     - 74 18.37 109 156 94 110 40 N N - - - - - - - - - -
14 40 M 1m     - 73 17.71 74 141 94 150 40 N N - - - - - - - - - -
15 72 M 7m     - 75 18.37 85 141 75 128 40 RC N - - - - - - - - - -
16 48 M 6m     - 70 19.53 69 144 76 138 40 N N - - - - - - - - - -
17 28 F 2Y     - 74 17.47 84 148 73 121 51 N N - - - - - - - - - -
18 32 M 4m     - 72 20.32 78 156 85 136 44 N N - - - - - - - - - -
19 48 M 6m     - 84 23.51 86 152 75 131 50 N N - -  + - - - - - - DEPRES
20 38 M 1m     - 82 20.32 91 171 89 142 54 N N - - - - - - - - - -
ERYTHRODERMIC PSORIASIS
S.NO Age Sex DD CD WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ?HDL MS MI OTHERS
1 34 F 3Y DM-2Y 94 28.3 92 166 105 120 37 FL N - -  + -    + -     +  + - ?WC, PRE OBESE
2 53 M 3Y     -   79 23.31 79 150 89 131 42 N N - - - - - - - - - -
3 50 M 15Y MI-16Y 95 26.93 73 178 111 144 38 FL IWMI - - - -    + -     + - + PRE OBESE
4 39 M 7Y     -   104 26.7 98 144 64 120 56 FL N - - - - - - - - - ?WC
5 48 M 1.5Y     -   74 21.21 92 140 89 70 37 N N - - - - - -     + - - -
6 58 M 4Y     -   86 17.45 87 147 90 108 25 N N - - - - - -     + - - -
7 45 F 2Y     -   75 22.64 68 211 90 104 36 N N - - -    + - -     + - - -
8 28 F 2Y     -   77 20.08 90 162 102 92 41 N N - - - -    + - - - - -
9 14 M 3m     -   70 17.36 92 198 128 150 40 N N - - - -    + - - - - -
10 65 M 3Y     -   84 22.06 91 194 115 141 51 N N - - - -    + - - - - -
11 52 M 3Y DM-8Y 86 32.92 268 223 147 210 34 FL N -  +   +    +    +     +     +   + - -
12 40 F 1Y HT-3Y 88 29.62 76 182 118 120 40 N N   + - - -    + - - - - PRE OBESE
13 48 F 15Y     -   100 24.44 98 198 119 142 51 N N   + - - -    + - -   - - ?WC
14 25 F 2Y     -   72 21.21 89 162 84 131 52 N N - - - - - - - - - -
PUSTULAR PSORIASIS
S.NO Age Sex DD CD PASI WC BMI FPG CHO LDL TGL HDL USG ECG HT OB DM ?CHO ?LDL ?TGL ? HDL MS MI OTHERS
1 22 F 22D - 38 84 23.57 73 182 96 165 53 N N - - - - - + - - - -
2 36 M 1m - 13.2 68 24.04 98 144 89 80 39 FL N - - - - - - + - - -
3 21 M 10D - 9.2 73 19.1 78 200 137 90 45 N N - - - - + - - - - -
4 23 M 2Y - 1.3 72 20.18 66 201 135 143 37 N N - - - + + - + - - -
5 30 M 2m - 7.4 75 19.05 66 174 118 87 39 N N - - - - + - + - - -
6 33 M 3m - 5.7 70 13.02 71 206 145 149 31 N N - - - + + - + - - -
7 38 F 10D - 3.3 86 26.22 62 196 104 282 36 FL N - - - - + + + - - PRE OBESE
8 20 F 10Y - 3.8 68 15.76 68 140 89 93 32 N N - - - - - - + - - -
9 33 F 2Y - 5.8 66 18.26 62 164 108 70 42 N N - - - - + - - - - -
10 50 M 6Y - 0.9 117 31.22 98 236 174 110 40 FL N -  + - + + - - - - ?WC
11 20 M 2Y - 4.8 68 17.72 73 147 93 84 37 N N - - - - - - + - - -
12 39 M 2Y - 2.6 100 32.05 89 184 125 128 33 FL N -  + - - + - - - - -
13 14 F 2Y - 0.9 67 16.22 72 134 66 83 51 N N - - - - - - - - - -
14 11 F 3m - 17.1 53 14.26 65 115 59 89 38 N N - - - - - - + - - -
15 9 M 5m - 3.8 56 16.26 93 140 79 89 43 N N - - - - - - - - - -
16 17 F 3Y - 7.4 62 16.23 70 251 184 80 51 N N - - - + + - - - - -
17 19 F 1Y - 5.8 73 18.96 84 159 97 124 34 N N - - - - - - + - - -
18 17 M 1Y - 3.6 69 16.6 87 168 93 178 39 N N - - - - - + + - - -
19 19 M 7Y - 4 72 19.05 96 150 72 132 52 N N - - - - - - - - - -
20 8 M 6m - 6.8 54 13.02 72 131 61 94 51 N N - - - - - - - - - -
21 58 F 3Y - 3.6 64 19.05 98 171 93 135 51 N N - - - - - - - - - -
22 23 M 3Y - 8.2 75 20.82 70 220 150 188 32 N N - - - + + + + - - -
GUTTATE PSORIASIS
KEY TO MASTER CHART
S.NO – Serial number
M – Male
F – Female
DD – Duration of disease
Y – Years
m  – Months
CD – Duration of comorbidity
PASI – Psoriasis area severity index
WC – Waist circumferance in cm
BMI – Body mass index
FPG – Fasting plasma glucose in mg/dl
CHO – Serum Cholesterol in mg/dl
LDL – Serum Low density lipoprotein in mg/dl
TGL – Serum Triglycerides in mg/dl
HDL – Serum High density lipoprotein in mg/dl
USG – Ultrasonogram abdomen
N – Normal
FL – Fatty liver
RC – Renal cyst
ECG – Electrocardiogram
ASMI – Anteroseptal Myocardial infraction
IWMI – Inferior wall Myocardial infraction
LVH – Left ventricular hypertrophy
UA – Unstable Angina
HT – Hypertension
OB – Obesity
DM – Diabetes mellitus
MS – Metabolic syndrome
MI – Myocardial infarction
DEPRES - Depression
PVD – Peripheral vascular disease
? – Increased
? – Decreased
? – Present
- – Absent
ABBREVATIONS
Th1 – T- helper cell 1
APC – Antigen presenting cell
TNF ? – Tumor Necrosis Factor ?
IL 2 – Interleukin 2
IFN  ? – Interferon ?
IL1 – Interleukin 1
IL6 – Interleukin 6
IL 17 ? – Interleukin17
IL20 – Interleukin20
Th17 – T-helper 17 cells
IL12 – Interleukin12
IL23 – Interleukin23
VEGF – Vascular Endothelial Growth  Factor
CAD – Coronary artery disease
OR – Odds ratio
CI – Confidence interval
P – p-value
BMI – Body Mass Index
TGL – Triglycerides
HDL – High Density Lipoprotein
LDL – Low Density Lipoprotein
VLDL – Very Low Density Lipoprotein
PASI – Psoriasis Area Severity Index
BSA – Body Surface Area
NECP – ATP III – National Cholesterol Education Programmes
Adult Panel III
NAFLD – Non-alcoholic Fatty Liver Disease
USG – Ultrasonogram
CT – Computed tomogram
MRI – Magnetic resonance imaging
COPD – Chronic Obsructive Pulmonary Dtsease
HT – Hypertension
OB – Obesity
DM – Diabetes Mellitus
DYS – Dyslipidemia
MS – Metabolic Syndrome
MI – Myocardial infraction
